Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mass Balance Study of [14C]TGRX-326 in Healthy Adult Chinese Male Participants

NCT06438367 is registered in ClinicalTrials.gov with Shenzhen TargetRx Co., Ltd. as lead sponsor.

NCT NCT06438367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06438367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mass Balance Study of [14C]TGRX-326 in Healthy Adult Chinese Male Participants
Lead sponsor
Shenzhen TargetRx Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
June 26, 2024
Completion date
July 21, 2024
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer